Fipravirimat is an experimental drug for the treatment of HIV/AIDS. It belongs to a class of drugs known as maturation inhibitors.[1][2]

Fipravirimat was being developed by ViiV Healthcare, but development was stopped in 2023.[3]

See also

References

  1. ^ "Fipravirimat". PubChem. U.S. National Library of Medicine.
  2. ^ Dicker I, Jeffrey JL, Protack T, Lin Z, Cockett M, Chen Y, et al. (January 2022). "GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile". Antimicrobial Agents and Chemotherapy. 66 (1): e0187621. doi:10.1128/AAC.01876-21. PMC 8765437. PMID 34780263.
  3. ^ Waldron, James (2023-04-26). "GSK drops one of 2 maturation inhibitors in HIV pipeline". Retrieved 2023-09-18.
Allikas: https://en.wikipedia.org/wiki/Fipravirimat
No tags for this post.